美国 · SEC Form 4 · 快照日期： 2026-10-19 · 构建时间： 2026-10-19 · English

美国 · SEC FORM 4

Dyne Therapeutics, Inc.

DYN · Nasdaq · CIK 0001818794 · Healthcare · Biotechnology

内部人信号

当前没有活跃买入信号

5 qualifying P purchase groups
当前 180 天评分窗口

98 同一窗口内观察到的 Form 4 交易行
92 sales · 1 期权、代扣税、授予、赠与或其他交易行

最近一次合资格买入2026-10-02 · Posner Brian S · $40.0K

为什么没有活跃信号？

买入活动存在

近期买入5 qualifying line group(s)

近期卖出High

买入信号状态未激活

评分构成

活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。

Cluster未计算

买入规模未计算

角色未计算

近期性未计算

确信度未计算

为什么没有分数？

没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。

卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。

买方广度与集中度

合资格买方1

买入集中度100%最大买方： Posner Brian S · $196.8K

聚集买入 · 15天1 insider峰值活动： 2026-05-20–2026-06-03

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct

Rhodes Jason PDirector

▼▼▼▼▼▼▼▼▼

Kerr DouglasChief Medical Officer

▼▼▼▼▼

Kersten DirkDirector

▼▼▼▼▼

Posner Brian SDirector

●●●●●

Friedl-Naderer JohannaChief Commercial Officer

▼▼▼▼

Cox JohnCEO & President

▼▼▼

● 买入▼ 卖出○ 其他

Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.

信号历史

暂无已记录的活跃信号快照

Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-10-02 · Posner Brian S.

近期 Form 4 活动

7买入

122卖出

5其他 Form 4 交易行

50SEC 申报 · 365天

买入5 qualifying P line(s) · 180 days

卖出92 sale line(s) · 仅供背景

其他1 exercise / withholding / award / gift / other lines

10b5-1／计划交易Not assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M: -9.7%
3M: -29.6%
6M: -10.9%
12M: +14.3%

波动率与流动性

波动率: 80.2%
Beta: —
平均每日成交额: USD 48.2M

估值

市值: USD 3.1B
P/E: —

基本面

利润率: —
ROE: -0.0%
细分行业: Biotechnology

市场数据

价格数据截至：2026-10-09 · 价格来源：OpenBB/yfinance; 成交量来自本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-07-24 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数: 25,977,390
上期报告: 23,381,047
日均成交量: 2,882,693
回补天数: 9.0

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction date	Reporting owner	类型	证券	股数	平均价格	估算金额	来源
2026-10-02	Posner Brian S	买入 (P)	Common Stock	2,500	USD 16.00	USD 40,000	SEC 申报 ↗
2026-06-08	Posner Brian S	买入 (P)	Common Stock	2,000	USD 16.94	USD 33,880	SEC 申报 ↗
2026-06-03	Posner Brian S	买入 (P)	Common Stock	2,500	USD 17.48	USD 43,700	SEC 申报 ↗
2026-05-26	Posner Brian S	买入 (P)	Common Stock	2,000	USD 18.21	USD 36,420	SEC 申报 ↗
2026-05-20	Posner Brian S	买入 (P)	Common Stock	2,500	USD 17.12	USD 42,800	SEC 申报 ↗
2026-03-11	Posner Brian S	买入 (P)	Common Stock	2,000	USD 19.35	USD 38,700	SEC 申报 ↗
2026-03-06	Posner Brian S	买入 (P)	Common Stock	3,000	USD 15.06	USD 45,180	SEC 申报 ↗
2025-07-14	Cox John	买入 (P)	Common Stock	100,000	USD 9.11	USD 911,000	SEC 申报 ↗
2024-09-04	Cox John	买入 (P)	Common Stock	8,000	USD 33.04	USD 264,304	SEC 申报 ↗
2024-01-09	Kersten Dirk	买入 (P)	Common Stock	1,714,285	USD 17.50	USD 29,999,988	SEC 申报 ↗
2022-12-12	Rhodes Jason P	买入 (P)	Common Stock	934,581	USD 10.70	USD 10,000,017	SEC 申报 ↗
2022-12-12	Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Opportunity Fund II, L.P.	买入 (P)	Common Stock	934,581	USD 10.70	USD 10,000,017	SEC 申报 ↗
2020-09-21	VIDA VENTURES II-A, LLC; VV Manager II, LLC; Vida Ventures II, LLC	买入 (P)	Common Stock	815,000	USD 19.00	USD 15,485,000	SEC 申报 ↗
2020-09-21	Logos Global Management LP	买入 (P)	Common Stock	700,000	USD 19.00	USD 13,300,000	SEC 申报 ↗
2020-09-21	Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; Shah Rajeev M.	买入 (P)	Common Stock	660,000	USD 19.00	USD 12,540,000	SEC 申报 ↗

Form 4 申报证据

134 transaction lines in the latest 365-day window; 614 in local history.

日期	申报人	类型	证券	股数	平均价格	估算金额	来源
2026-10-02	Posner Brian S	买入 (P)	Common Stock	2,500	USD 16.00	USD 40,000	SEC 申报 ↗
2026-09-08	Kerr Douglas	卖出 (S)	Common Stock	1,290	USD 18.88	USD 24,355	SEC 申报 ↗
2026-09-08	Friedl-Naderer Johanna	卖出 (S)	Common Stock	185	USD 18.88	USD 3,493	SEC 申报 ↗

展开近期 Form 4 证据 (30 grouped rows)

日期	申报人	类型	证券	股数	平均价格	估算金额	来源
2026-10-02	Posner Brian S	买入 (P)	Common Stock	2,500	USD 16.00	USD 40,000	SEC 申报 ↗
2026-09-08	Kerr Douglas	卖出 (S)	Common Stock	1,290	USD 18.88	USD 24,355	SEC 申报 ↗
2026-09-08	Friedl-Naderer Johanna	卖出 (S)	Common Stock	185	USD 18.88	USD 3,493	SEC 申报 ↗
2026-09-08	Cox John	卖出 (S)	Common Stock	5,658	USD 18.88	USD 106,823	SEC 申报 ↗
2026-09-04	Kerr Douglas	卖出 (S)	Common Stock	3,745	USD 24.35	USD 91,191	SEC 申报 ↗
2026-09-04	Friedl-Naderer Johanna	卖出 (S)	Common Stock	900	USD 24.35	USD 21,915	SEC 申报 ↗
2026-08-14	Rhodes Jason P	卖出 (S)	Common Stock	2,160,516	USD 25.00	USD 54,012,900	SEC 申报 ↗
2026-08-13	Rhodes Jason P	卖出 (S)	Common Stock	426,412	USD 26.20	USD 11,171,994	SEC 申报 ↗
2026-08-13	Lucera Erick	卖出 (S)	Common Stock	1,797	USD 26.28	USD 47,225	SEC 申报 ↗
2026-08-13	Kerr Douglas	卖出 (S)	Common Stock	1,556	USD 26.28	USD 40,892	SEC 申报 ↗
2026-08-13	Friedl-Naderer Johanna	卖出 (S)	Common Stock	226	USD 26.28	USD 5,939	SEC 申报 ↗
2026-08-13	Cox John	卖出 (S)	Common Stock	4,986	USD 26.28	USD 131,032	SEC 申报 ↗
2026-07-27	Kersten Dirk	卖出 (S)	Common Stock	261,460	USD 25.51	USD 6,670,140	SEC 申报 ↗
2026-07-07	Rhodes Jason P	卖出 (S)	Common Stock	297,211	USD 23.26	USD 6,913,822	SEC 申报 ↗
2026-07-06	Rhodes Jason P	卖出 (S)	Common Stock	480,240	USD 22.79	USD 10,944,670	SEC 申报 ↗
2026-06-29	Rhodes Jason P	卖出 (S)	Common Stock	195,427	USD 21.14	USD 4,131,327	SEC 申报 ↗
2026-06-26	Rhodes Jason P	卖出 (S)	Common Stock	309,268	USD 21.28	USD 6,581,223	SEC 申报 ↗
2026-06-25	Rhodes Jason P	卖出 (S)	Common Stock	24,100	USD 21.10	USD 508,510	SEC 申报 ↗
2026-06-25	Lucera Erick	卖出 (S)	Common Stock	2,362	USD 20.37	USD 48,114	SEC 申报 ↗
2026-06-24	Rhodes Jason P	卖出 (S)	Common Stock	95,900	USD 21.02	USD 2,015,818	SEC 申报 ↗
2026-06-23	Rhodes Jason P	卖出 (S)	Common Stock	147,760	USD 21.13	USD 3,122,169	SEC 申报 ↗
2026-06-23	Kersten Dirk	卖出 (S)	Common Stock	73,286	USD 21.05	USD 1,542,650	SEC 申报 ↗
2026-06-22	Kersten Dirk	卖出 (S)	Common Stock	190,676	USD 20.57	USD 3,922,205	SEC 申报 ↗
2026-06-18	Kersten Dirk	卖出 (S)	Common Stock	46,901	USD 20.07	USD 941,303	SEC 申报 ↗
2026-06-17	Kersten Dirk	卖出 (S)	Common Stock	37,454	USD 20.14	USD 754,324	SEC 申报 ↗
2026-06-16	Kerr Douglas	卖出 (S)	Common Stock	887	USD 18.33	USD 16,259	SEC 申报 ↗
2026-06-16	Friedl-Naderer Johanna	卖出 (S)	Common Stock	145	USD 18.33	USD 2,658	SEC 申报 ↗
2026-06-16	Cox John	卖出 (S)	Common Stock	2,683	USD 18.33	USD 49,179	SEC 申报 ↗
2026-06-08	Posner Brian S	买入 (P)	Common Stock	2,000	USD 16.94	USD 33,880	SEC 申报 ↗
2026-06-03	Posner Brian S	买入 (P)	Common Stock	2,500	USD 17.48	USD 43,700	SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期	2026-10-19
排名版本	US-v1.2
数据质量	PASS ELIGIBLE · —
股票代码	DYN
CIK	0001818794
行业	Healthcare
细分行业	Biotechnology Yahoo Finance
SEC SIC	2834 Pharmaceutical Preparations
交易所	Nasdaq

数据覆盖

本地 Form 4 历史	614 transaction lines from 2020-09-17 to 2026-10-02 18 P purchase lines · 461 S sale lines · 135 other lines
SEC 公司申报	打开 SEC 申报 ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.